TOday’s Movers: miRagen Therapeutics Inc (MGEN) Stock Rating Reconfirmed by Wedbush; $19.0 Target Price Indicates 168.74 % Potential

March 14, 2018 - By Migdalia James

 TOday’s Movers: miRagen Therapeutics Inc (MGEN) Stock Rating Reconfirmed by Wedbush; $19.0 Target Price Indicates 168.74 % Potential

miRagen Therapeutics Inc (MGEN) Rating Reaffirmed

EU: In a note issued to clients and investors on 1 December, Wedbush reaffirmed their “Buy” rating on miRagen Therapeutics Inc (MGEN) shares. They now have a $19.0 target price on the firm. Wedbush’s target suggests a potential upside of 168.74 % from the company’s previous close.

Miragen Therapeutics, Inc. (NASDAQ:MGEN) Ratings Coverage

Among 7 analysts covering Miragen Therapeutics (MGEN), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Miragen Therapeutics has $19.0 highest and $13.0 lowest target. $16.40’s average target is 131.97% above currents $7.07 stock price. Miragen Therapeutics had 11 analyst reports since February 21, 2017 according to SRatingsIntel. The company was maintained on Friday, February 2 by FBR Capital. Wedbush maintained Miragen Therapeutics, Inc. (NASDAQ:MGEN) on Monday, October 16 with “Buy” rating. The company was maintained on Monday, August 14 by Chardan Capital Markets. The company was initiated on Thursday, January 11 by Oppenheimer. The rating was maintained by Wedbush with “Buy” on Friday, August 18. The company was maintained on Friday, December 1 by Wedbush. The rating was initiated by Wedbush with “Outperform” on Tuesday, February 21.

The stock increased 0.71% or $0.05 during the last trading session, reaching $7.07. About 223,355 shares traded. Miragen Therapeutics, Inc. (MGEN) has 0.00% since March 14, 2017 and is . It has underperformed by 16.70% the S&P500.

Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. The company has market cap of $207.16 million. The Company’s two lead product candidates, MRG-106 and MRG-201 are in Phase 1 clinical trials. It currently has negative earnings. The companyÂ’s clinical product candidate for the treatment of certain cancers, MRG-106, is an inhibitor of microRNA-155, which is found at abnormally high levels in various blood cancers.

More notable recent Miragen Therapeutics, Inc. (NASDAQ:MGEN) news were published by: which released: “Miragen Therapeutics May Provide Long-Term Alpha Within The RNA Space” on February 01, 2018, also with their article: “miRagen Therapeutics to Report Fourth Quarter and Full Year 2017 Financial …” published on March 07, 2018, published: “miRagen Therapeutics to Present at the Cantor Fitzgerald Global Healthcare …” on September 01, 2017. More interesting news about Miragen Therapeutics, Inc. (NASDAQ:MGEN) were released by: and their article: “miRagen Therapeutics (MGEN) Announces Proposed 7M Share Common Offering” published on February 05, 2018 as well as‘s news article titled: “miRagen Therapeutics to Announce Third Quarter 2017 Financial Results and Host …” with publication date: November 01, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: